Venkat Mocherla
speaker
203 appearances
2 recordings
1 series
first heard Jan 2025
last heard Feb 2025
Venkat Mocherla’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Yeah, thank you, Scott. Gosh, it's such a, you know, I have to say, you know, long-time listener, first-time caller type of thing. You know, so great to be with you and the community you've built at Becker's. Yeah, just to introduce myself, as Scott said, I'm Venkat Macharla. I'm the co-founder of Midstream Health.
I've been thinking about and working in the intersection of healthcare and technology for, boy, 15 years now. You know, I got to go start my career at a large care delivery provider called DaVita. And at the time, we were thinking a lot about not just, you know, kidney care, but actually how do we sort of build new businesses.
And I got to be fortunate enough to be part of a team that was, you know, revolutionizing primary care using these direct primary care models and a company called Palladina at the time. It's now part of Marathon Health. Um, I got to, you know, work on some new value-based care models there.
And then, um, I worked globally, uh, in the middle East and Europe and Canada, um, for a consulting research and technology company called the advisory board, which many of your listeners might know of. And then about 10 years ago, got obsessed with the intersection of AI and healthcare delivery. Um, I got to see a company go launch off the ground and a company called Juventus, um,
which is still and now is one of the leaders in applying AI for clinical operations. And 10 years ago, boy, you know, it's so interesting. Some of these trends take a while to catch up. And 10 years ago, nobody was really applying AI for some of these solutions. And now there's a whole host of entrepreneurs and interest and excitement in that area.
And then, as you said, got to be fortunate enough to be part of the incredible venture capital firm, Andreessen Horowitz, for about five years. And I got to partner with many entrepreneurs and helping them bring some of these ideas to scale.
And then not too long ago, got to start my own company called Midstream Health, where we think about fundamentally how do we accelerate and advance financial sustainability using AI for some of the largest healthcare systems in the country. So that's a little bit about me, Scott.
Yeah, I've been fortunate, whether as an angel investor in companies or partner with entrepreneurs at Andreessen Horowitz, invested in this part of healthcare,
One of the, I think there's some very interesting, I think, friends that I think are worth observing if you take one step back and think through some of the patterns that we see now, because I've been fortunate enough to, you know, from the days of Kivanos to A16Z to my own company now at Midstream, got to see some of these patterns play through.
I think there's three acts that have really been revolutionary and transformative and I think are fundamentally quite exciting.
for both founders and for patients and for, you know, clinical and administrative leaders in healthcare, which is, I think, the first kind of trend that I think is so powerful for AI is we talk about all these sort of magical applications like chat GPT or perplexity or whatever you're using. Or, you know, if you come to San Francisco, it's a pretty magical experience.
And now it's in Arizona and a couple of the markets, which is, getting into a Waymo before all of these sort of applied AI applications, you really have to figure out the data piece. And I think we don't talk about that enough. And so, you know, after the high-tech act, we really kicked off. I think we, you know, the example I give is like the human genome project, right.
Where we got to sequence all the DNA to throw out all these magical medicines we can do, um, you know, with genetics. I think there's a corollary there of actually sequencing, I call it the business genome, which is like, how do you capture the data, whether it's from other systems or record like the EMR, Epic, whether it's ERP systems. There's a lot of mapping.
If you remember back in the day, if you think about using Google Maps, there's a car that's going across every street in America and capturing that picture. There's that work of sequencing the business genome that I think it has made all of these companies even possible in these applications. So that's trend one that I think is so powerful.
I think trend two that I think is so interesting and fascinating is people's superpowers. So what do I mean by that? Clinicians are incredibly burnt out. Why are they burnt out? A big part of that driver is what we call pajama time. They're doing clinical notes after seeing a really busy day of patients.
And instead of now typing into the keyboard, you have these ambient devices that can give, basically take their notes on their behalf and summarize it and input it into the EMR with some supervision.
Same thing on the administrative side, like how do you give people superpowers around managing your, you know, or, you know, doing block optimization if you're, if you're Coventus or in the case of Midstream, how are you thinking about financial decisions that are across the, you know, very complex supply chain or the pharmacy or managed care and other areas?
So I think, you know, this era of superpowers has sort of unleashed a big opportunity set. The third thing I'll sort of say from a patient perspective is there's a, you know, I think about it as like autonomy in healthcare. So, you know, I talked about the Waymo example where, you know, you have, you know, the self-driving world, actually, you know, this is inspired by DARPA,
they put a framework around how do you think about self-driving cars. So there's a framework that starts with an L1, level one. They give it some basic, you know, cruise control type stuff to like L5, which is like, you know, your fully autonomous car.
I think we're going through that journey right now from a patient perspective because, you know, how do you think about this very reactive system we sit in today compared to,
Showing 1–20 of 203 · page 1 of 11
Next →